--- title: "RenovoRx (RNXT) news: going concern, offering and Nasdaq notice" url: "https://aibio.space/companies/renovorx/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RNXT going concern, offering and Nasdaq notice news: RenovoRx prices 11,523,810-share offering at $1.05 for $12,100,001 in gross proceeds. RenovoRx, Inc." --- RNXT RenovoRx, Inc. NASDAQ · United States # RenovoRx (RNXT) news RNXT going concern, offering and Nasdaq notice news Financings · 2026-03-23 ## [RenovoRx closes private placement for about $10 million in gross proceeds](https://aibio.space/news/renovorx-closes-private-placement-about-10-million-gross-proceeds/) RenovoRx (Nasdaq: RNXT) sold 8,438,790 shares, pre-funded warrants and revenue milestone warrants to 15 investors, five of them insiders. The deal closed March 20, 2026. ## Latest RenovoRx news 1. 2025-03-31 Distress [RenovoRx files NT 10-K, says annual report will be late](https://aibio.space/news/renovorx-files-nt-10-k-says-annual-report-will-late/) RenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period. 2. 2025-03-31 Distress [RenovoRx files late notice for 2024 annual report, cites auditor accounting work](https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/) RenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period. 3. 2025-02-06 Financings [RenovoRx prices 11,523,810-share offering at $1.05 for $12,100,001 in gross proceeds](https://aibio.space/news/renovorx-prices-11-523-810-share-offering-1-05-12-100-001-gross/) RenovoRx sold 11,523,810 shares at $1.05, below the $1.46 last sale on February 6, 2025, with Titan Partners Group as sole bookrunner. The company held about $9.6 million in cash and short-term securities at September 30, 2024, and its prospectus carries a going concern paragraph. ## RenovoRx at a glance - **Ticker**: RNXT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.5 million ### Related companies - [Anika Therapeutics](https://aibio.space/companies/anika-therapeutics/) NASDAQ: ANIK - [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) AMEX: SER - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [Apollomics](https://aibio.space/companies/apollomics/) NASDAQ: APLM - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH ### Also on NASDAQ - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) MGRX - [ASP Isotopes](https://aibio.space/companies/asp-isotopes/) ASPI - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) ANTX - [Opus Genetics](https://aibio.space/companies/opus-genetics/) IRD - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) CLRB ## RenovoRx annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | [$43,000](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | | Research and development | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | | Net income (loss) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | [-$8.8 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | | Cash from operations | [-$11.0 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | [-$9.1 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | | Cash and equivalents | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526349190/) | [$7.2 million](https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about RenovoRx Has RenovoRx issued a going-concern warning? Our latest story on this, dated Feb 6, 2025: "RenovoRx prices 11,523,810-share offering at $1.05 for $12,100,001 in gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/renovorx-prices-11-523-810-share-offering-1-05-12-100-001-gross/). Has RenovoRx raised money recently? Our latest story on this, dated Mar 23, 2026: "RenovoRx closes private placement for about $10 million in gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/renovorx-closes-private-placement-about-10-million-gross-proceeds/). Has RenovoRx received a Nasdaq deficiency notice? Our latest story on this, dated Mar 31, 2025: "RenovoRx files NT 10-K, says annual report will be late". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/renovorx-files-nt-10-k-says-annual-report-will-late/). What is the ticker symbol of RenovoRx? RenovoRx, Inc. trades under the ticker RNXT on NASDAQ. Where is RenovoRx listed? RenovoRx, Inc. is listed on NASDAQ. What is the SEC CIK of RenovoRx? The SEC Central Index Key (CIK) for RenovoRx, Inc. is 1574094. Its filings are on SEC EDGAR. How many shares does RenovoRx have outstanding? 45,129,508 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is RenovoRx listed under? Our directory records RenovoRx, Inc. under United States. What does RenovoRx do? Our directory classifies RenovoRx, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of RenovoRx? The ISIN recorded for RenovoRx, Inc. is US75989R1077. Does aibio.space cover RenovoRx? aibio.space lists RenovoRx, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is RenovoRx incorporated? SEC records list its state or country of incorporation as DE. What was RenovoRx's revenue last year? $1.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is RenovoRx profitable? RenovoRx, Inc. reported a net loss of $11.2 million for the fiscal year ended Dec 31, 2025, and used $11.0 million of cash in operations, per its annual report to the SEC. How much does RenovoRx spend on research and development? $6.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: RenovoRx Members talk about RenovoRx (RNXT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at RenovoRx, newest first. Each line links the filing it comes from. 1. 2026-08-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315226039472/form8-k.htm) 2. 2026-07-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315226031662/form8-k.htm) 3. 2026-03-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/ex99-1.htm) 4. 2026-01-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315226000113/form8-k.htm) 5. 2025-11-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315225022304/form10-q.htm) 6. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1574094/000164117225001842/formnt10-k.htm) 7. 2025-02-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315225005201/form424b5.htm) 8. 2024-11-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1574094/000149315224045137/form10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RNXT on TradingView](https://www.tradingview.com/symbols/NASDAQ-RNXT/). ## SEC filings and registration - **SEC name**: RenovoRx, Inc. - **CIK**: 1574094 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: RNXT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040 - **Phone**: 408-800-2649 - **Shares outstanding**: 45,129,508 as of 2026-08-07 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1574094/000149315226039472/form8-k.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1574094/000119312526349190/rnxt-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/rnxt-20260812.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/form8-k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1574094/000149315226031662/form8-k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1574094/000149315226031303/form8-k.htm) filed 2026-06-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1574094/000119312526224100/rnxt-20260331.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/rnxt-20260514.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001574094), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details RenovoRx, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RNXT, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: RenovoRx, Inc. - **Ticker**: RNXT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US75989R1077 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RNXT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/renovorx/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "RenovoRx (RNXT) news: going concern, offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/renovorx/